3 Fermentation Ingredients Maker, Generics and Branded Medicines Company and Portable Molecular Testing Firm Stocks With a Strong Future Roadmap: Concord Biotech, Alembic Pharmaceuticals and Molbio Diagnostics
- October 27, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Concord Biotech, Alembic Pharmaceuticals and Molbio Diagnostics: ROE of 11.9% to 14.2% and FY22 to FY26 revenue CAGR of 8.4% to 16.8%. Prices as of 26 Oct 2026.
Quick Answer
The three fermentation API, generics and testing stocks to watch are Concord Biotech, Alembic Pharmaceuticals and Molbio Diagnostics. Their return on equity ranges from 11.9% to 14.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 16.8%. Molbio Diagnostics leads on both return on equity at 14.2% and revenue growth at 16.8% a year. Prices are based on the 26 October 2026 close, and this article is educational, not investment advice.
Fermentation API, generics and testing stocks let investors follow companies that serve a growing part of the Indian economy. Concord Biotech, Alembic Pharmaceuticals and Molbio Diagnostics cover a fermentation ingredients maker, a generics and branded medicines company and a portable molecular testing firm.
This list covers three fermentation API, generics and testing stocks with complete current figures: Concord Biotech, Alembic Pharmaceuticals and Molbio Diagnostics. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Fermentation API, Generics and Testing Stocks?
Fermentation API, generics and testing stocks are listed healthcare companies that make fermentation based ingredients, generic and branded medicines and portable disease tests. Their earnings depend on global orders, product launches, approvals and testing demand.
Fermentation API, Generics and Testing Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Concord Biotech | 1,311.2 | 13,421 | 49.2 | 36.0 | 12.9 | 0.00 |
| Alembic Pharmaceuticals | 766.4 | 14,914 | 21.6 | 35.7 | 11.9 | 0.25 |
| Molbio Diagnostics | 1,273.5 | 16,605 | 101.2 | 59.6 | 14.2 | 0.38 |
On valuation, Alembic Pharmaceuticals trades at a P/E below the industry P/E, while Concord Biotech and Molbio Diagnostics trade above it, which reflects the growth the market already expects. Readers comparing fermentation API, generics and testing stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Fermentation API, Generics and Testing Stocks Have a Strong Roadmap in India?
Fermentation API, generics and testing stocks have a strong roadmap in India because global buyers add dependable ingredient suppliers, branded and generic medicines keep gaining reach and portable testing widens access to diagnosis.
- Ingredient supply. Global drug makers add Indian suppliers.
- Product launches. New generics and brands widen markets.
- Point of care tests. Portable devices reach remote areas.
Why Concord Biotech Features Among These Fermentation API, Generics and Testing Stocks
Among the fermentation API, generics and testing stocks on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.
The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.
Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore.
Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
What to watch: Monitor the pace of new product introductions and the contribution from formulations.
Why Alembic Pharmaceuticals Features Among These Fermentation API, Generics and Testing Stocks
Among the immunosuppressant ingredient shares on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.
Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%.
In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.
Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.
Why Molbio Diagnostics Features Among These Fermentation API, Generics and Testing Stocks
Among the three companies on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.
Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.
Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.
Concord Biotech vs Alembic Pharmaceuticals vs Molbio Diagnostics on Key Financials
The table below sets the three fermentation API, generics and testing stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Concord Biotech | 736 | 1,107 | 10.7% | 259 | 23.4% |
| Alembic Pharmaceuticals | 5,356 | 7,399 | 8.4% | 671 | 9.1% |
| Molbio Diagnostics | 782 | 1,455 | 16.8% | 164 | 11.3% |
Molbio Diagnostics posts the highest return on equity in this group at 14.2%. Alembic Pharmaceuticals has the largest FY26 revenue at Rs 7,399 crore, and Molbio Diagnostics shows the fastest revenue growth with a 16.8% compound annual rate. A useful habit with fermentation API, generics and testing stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Fermentation API, Generics and Testing Stocks
Every theme carries risks that deserve a check before any decision. For these fermentation API, generics and testing stocks, the main points are: Long-term immunosuppressant ingredient shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Order timing. Large contracts can shift between periods.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter fermentation API, generics and testing stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Fermentation API, Generics and Testing Stocks
Fermentation API, generics and testing stocks reward investors who follow demand trends, order books and margins together. Concord Biotech, Alembic Pharmaceuticals and Molbio Diagnostics each have a clear plan to grow. Based on the 26 October 2026 close, Concord Biotech trades at Rs 1,311.2, Alembic Pharmaceuticals at Rs 766.4 and Molbio Diagnostics at Rs 1,273.5.
Download the Univest iOS App or Univest Android App to track fermentation API, generics and testing stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are fermentation API, generics and testing stocks?
Ans. Fermentation API, generics and testing stocks are listed healthcare companies that make fermentation based ingredients, generic and branded medicines and portable disease tests. Their earnings depend on global orders, product launches, approvals and testing demand. This list looks at three of them, Concord Biotech, Alembic Pharmaceuticals and Molbio Diagnostics, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.
Which fermentation API, generics and testing stocks are covered in this list?
Ans. This list covers Concord Biotech, Alembic Pharmaceuticals and Molbio Diagnostics. Based on the 26 October 2026 close, Concord Biotech traded at Rs 1,311.2, Alembic Pharmaceuticals at Rs 766.4 and Molbio Diagnostics at Rs 1,273.5. Their return on equity ranges from 11.9% to 14.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 16.8%.
Why do fermentation API, generics and testing stocks have a strong future roadmap in India?
Ans. Fermentation API, generics and testing stocks have a strong roadmap in India because global buyers add dependable ingredient suppliers, branded and generic medicines keep gaining reach and portable testing widens access to diagnosis. The main drivers are as follows. Ingredient supply. Global drug makers add Indian suppliers. Product launches. New generics and brands widen markets. Point of care tests. Portable devices reach remote areas. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Concord Biotech performed financially?
Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
How has Alembic Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
How has Molbio Diagnostics performed financially?
Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What risks should investors check before buying fermentation API, generics and testing stocks?
Ans. Investors should check a few risks before buying fermentation API, generics and testing stocks. Regulatory checks. Plant inspections can affect approvals. Order timing. Large contracts can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of fermentation API, generics and testing stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
